The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
 
Brian Andrew Van Tine
Consulting or Advisory Role - Caris Life Sciences; CytRx Corporation; EMD Serono; Johnson & Johnson; Lilly/ImClone; Novartis; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; Johnson & Johnson; Lilly; Novartis
Research Funding - Merck; Pfizer
Expert Testimony - Me1 Patient
 
Nam Bui
No Relationships to Disclose
 
Bethany Prudner
No Relationships to Disclose
 
John S. Bomalaski
Employment - Polaris
Leadership - Polaris
Stock and Other Ownership Interests - Polaris
Patents, Royalties, Other Intellectual Property - Patents
Travel, Accommodations, Expenses - Polaris
 
Bor-Wen Wu
Employment - Polaris
Leadership - Polaris
Stock and Other Ownership Interests - Polaris
Patents, Royalties, Other Intellectual Property - Patents
Travel, Accommodations, Expenses - Polaris
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Kristen N. Ganjoo
Consulting or Advisory Role - Daiichi Sankyo; Immune Design; Janssen; Lilly; Novartis
 
Peter John Oppelt
Speakers' Bureau - Bristol-Myers Squibb
 
Angela C. Hirbe
No Relationships to Disclose